Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Japanese, Phase 2, Multicenter, Randomized, 4-arm Parallel, Double-blind (Arms 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis-dependent Chronic Kidney Disease Patients With Anemia
Brief Summary: This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.


Options:
A: Arm Label: GSK1278863 4 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 12 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 12 mg, GSK1278863 4 mg, GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Control
B: Arm Label: Daprodustat treated anemic subjects; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Iron therapy | Arm Label: Darbepoetin alfa treated anemic subjects; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat treated anemic subjects | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa treated anemic subjects | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat treated anemic subjects, Darbepoetin alfa treated anemic subjects
C: Arm Label: ASP1517 Low dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 Middle dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 High dose group, ASP1517 Low dose group, ASP1517 Middle dose group | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Darbepoetin group
D: Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Arm Label: Participants receiving Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Acetylcholine; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Sodium nitroprusside; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: L-N-monomethyl arginine acetate (L-NMMA); Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa

Answer: C